BASIL 2 - search results
If you're not happy with the results, please do another search
Endovascular showdown: CX 2024 sets the stage for BASIL-3 first-time data presentations
At the Charing Cross (CX) Symposium 2024 (23–25 April, London, UK), Andrew Bradbury (University of Birmingham, Birmingham, UK) and the BASIL-3 team of triallists...
VAM 2023 attendees have their say on the impact of BEST-CLI and BASIL-2 trials
As the vascular community continues to unpack the key learnings from two of the biggest trials to date in chronic limb threatening ischemia—BEST-CLI and...
VAM attendees chime in on BEST-CLI and BASIL-2
VS@VAM journalist Will Date and videographer Jean-Philippe Bensoussan caught some VAM 2023 foot traffic outside the BEST-CLI and BASIL-2: Debate, Analysis and Implementation session...
BEST-CLI vs. BASIL-2: Different questions yield different answers
Medical editor Malachi Sheahan III, MD, takes a look at seemingly conflicting results from the landmark BEST-CLI and BASIL-2 trials, and asks what they...
BASIL-2 and BEST-CLI: A tale of two limb trials
Optimal treatment of patients with chronic limb-threatening ischemia (CLTI) has been an ongoing debate within the vascular community, fueled by growing numbers of patients,...
BASIL-2 points towards endovascular-first revascularization strategy in CLTI patients
A question from Manj Gohel, MD, from Cambridge University Hospitals in Cambridge, England, on what the 2023 Charing Cross (CX) International Symposium audience should...
BEST-CLI and the BASIL trials: Motion sees audience move in favor of endovascular therapy...
During the 2024 Charing Cross (CX) International Symposium in London, England (April 23–25), a Great Debate that pitted four global peripheral arterial disease (PAD)...
Vascular Specialist–May 2024
In this issue:
Questions linger: BASIL-3 does not find for drug-eluting technologies for CLTI
Guest Editorial: Aortas, open surgical skills and gratitude
Vascular training:...
Questions linger: BASIL-3 does not find for drug-eluting technologies for CLTI
In the UK National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA)-funded BASIL-3 randomised controlled trial (RCT), neither drug-coated balloon (DCB)...
Vascular Specialist–April 2024
In this issue:
Bad reading: Worrying new data demonstrate a consistent shortfall of more than a fifth in net revenues over a four-year period...
TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough for below-the-knee arteries
Results of the LIFE-BTK randomized controlled trial have just been presented at TCT 2023 (Oct. 23–26) in San Francisco. The data show that, in...
Obituary: Roger M. Greenhalgh (Feb. 6, 1941–Oct. 6, 2023)
Roger Malcolm Greenhalgh, MD, the surgeon internationally renowned for his unparalleled contribution to vascular education, training and research, died peacefully on Oct. 6. He...
The top 10 most popular Vascular Specialist stories of June 2023
Last month, Vascular Specialist garnered readers' attention with an array of commentary on the BEST-CLI and BASIL-2 trials; the medical editor's interview with vascular...
VAM 2023 beckons
Our annual gathering is almost here. After months of planning, our premiere educational event in vascular surgery, the Vascular Annual Meeting (VAM), opens June...
Vascular Specialist–June 2023 VAM special
In this VAM 2023 preview issue:
The Vascular Annual Meeting (VAM) beckons: "Our annual gathering is almost here. After months of planning, our premiere...
Vascular Specialist–May 2023
In this month's issue:
BASIL-2 points towards endovascular-first revascularization strategy in CLTI patients (p. 1 and 3)
A vascular mission: Defying assumptions in the...
The top 10 most popular Vascular Specialist stories of April 2023
In April 2023, Vascular Specialist readers were drawn to an interview dissecting the role robotics play, and can play in the future, in vascular...
VAM 2023 meeting set to take place as exclusively in-person event
A block party on opening day, session recordings available daily and—of course—the educational and scientific sessions for which the Society for Vascular Surgery’s Vascular...
Roundtable for treating CLTI: GLASS will make it clear
The final of three roundtables on treating Chronic Limb-threatening Ischemia (CLTI) will cover the Global Limb Anatomic Staging System—GLASS.
The virtual roundtable, on GLASS staging...
Cost-effectiveness outcomes defy expectations in latest BEST-CLI data drop
The open surgical approach will prove to be “slightly superior” to endovascular intervention in terms of cost per life year gained, while the latter...
New study validates BEST-CLI trial results, ‘suggesting generalizability’
A new propensity-matched analysis of more than 1,100 lower extremity revascularization procedures carried out in patients with chronic limb-threatening ischemia (CLTI)—which aimed to help...
Novel bioabsorbable perivascular wrap aims to reduce AVF failure
Ellen Dillavou, MD, division chief of vascular surgery at WakeMed Heart Center in Raleigh, North Carolina, primary investigator (PI) for the VenoStent trial, presented...
Research suggests arm vein is the best alternative bypass conduit to GSV in patients...
A new analysis has found arm vein to be the most suitable alternative conduit to great saphenous vein (GSV) in chronic limb-threatening ischemia (CLTI)...
APDVS launches vascular surgery curriculum e-book for medical students
The Association of Program Directors in Vascular Surgery (APDVS) has released a new ebook designed to enhance vascular surgery education for medical students. According...
VQI analysis of CLTI practice following BEST-CLI finds no pick up in bypass rate
A Vascular Quality Initiative (VQI) analysis of evolving practice in the wake of the BEST-CLI trial demonstrated no increase in the rate of surgical...
SCOREPAD seeks to address ‘alarmingly high’ mortality in CLTI patients with underlying coronary disease
A new research letter underscores the need to improve long-term survival following lower extremity revascularization for chronic limb-threatening ischemia (CLTI), setting out a randomized...
BEST-CLI: A year down the road
A dedicated session at the 2023 VEITHsymposium (Nov. 14–18) in New York City aimed to unpack the ways in which clinical practice and attitudes...
When women are PIs: A story foretold on the vascular frontlines
“Multifactorial” issues persist in gender representation in vascular leadership and trial enrollment, leading women vascular surgeons tell Vascular Specialist.
"We would have fewer untoward side...
Second edition of VSITE review text released
The second edition of a hit trainee-created textbook primarily aimed at those taking the Vascular Surgery In-Training Exam (VSITE) has hit the shelves.
The Vascular...
Special VAM session underscores ‘complementary’ nature of open and endovascular strategies in CLTI patients
A dedicated session at VAM 2023 saw speakers and delegates gather to debate, analyse and consider the implementation of the BEST-CLI and BASIL-2 randomized-controlled...
VAM educational sessions set to cover gamut of clinical and vascular practice matters
With sessions covering a wide swath of topics important to vascular surgeons, including many proposed by Society for Vascular Surgery (SVS) members themselves, participants...
On 45th anniversary, CX Symposium chairman credits Chicago vascular surgical tandem for enduring success
The occasion of a seminal meeting held in Chicago by former Society for Vascular Surgery (SVS) Presidents John J. Bergan, MD, and James S.T....
VEITHsymposium to include world federation session
The World Federation of Vascular Societies (WFVS) is set to hold a session in November during the VEITHsymposium in New York City. The 90-minute session...
Intraoperative vascular mapping during hemodialysis access ‘should be incorporated into routine practice’
Intraoperative ultrasonographic venous mapping is a useful tool to evaluate vessel suitability for arteriovenous fistula (AVF) creation, Yana Etkin, MD, associate professor of surgery...
First results from BEST-CLI poised to reveal ‘very low’ quality of life for patients...
An analysis from the Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial presented at the 2022 Vascular Annual...
Houston, we have a dialysis access problem
The concept of dedicated vascular access centers fuels a turbocharged Texan tussle with Karl Illig, MD, of Flow Vascular Institute in Houston, taking on Eric...
CLI at a crossroads: Which direction now?
Vascular surgery once again finds itself at a crossroads, Michael Belkin, MD, chief of the division of vascular and endovascular surgery at Brigham and...
Benefits of percutaneous fistula creation further bolstered by five-year Ellipsys data
The Ellipsys vascular access system (Avenu Medical/Medtronic) can be used to easily and safely create durable percutaneous arteriovenous fistulas (pAVFs) for haemodialysis—with new, long-term...
‘Proceed cautiously in use of DCBs in CLTI patients with advanced WIfI stage’
The last several years have seen ongoing controversy and debate about the risks and benefits of paclitaxel-coated devices (PCDs) for patients with peripheral arterial...
TCAR may be associated with favorable outcomes in restenotic carotid lesions, study suggests
Transcarotid artery revascularization (TCAR) may be associated with favorable in-hospital outcomes for the treatment of restenotic carotid lesions after carotid endarterectomy (CEA), suggests a...
The paclitaxel paradox
As medical editor of Vascular Specialist, it has always been my hope to use our excellent reporters and rapid production schedule to keep readers...
Disappearing Act
By now you must be tired of my rants about other specialties making inroads into our “turf.” But a brochure came across my desk...
UPDATE: Enrollment in BEST-CLI study is well underway
In the past few months the BEST-CLI study has continued to energetically enroll patients. More than 100 of the planned 120 trial sites have...
Choosing Wisely: A good start to explaining vascular best practices
Choosing Wisely was initiated by the American Board of Internal Medicine Foundation to provide recommendations to both patients and physicians about the evaluation and...
Ancient Aneurysms
Before anesthetics, before antibiotics, before surgery had even become a scientific discipline, surgeons throughout history did not shy away from the treatment of aneurysms,...
The FREEDOM trial: Is it sui generis?
I have never understood how the cardiology community is able to organize so many excellent trials while vascular surgeons struggle to complete a small...
Endovascular Therapy First for All CLI?
The Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease (TASC I), published in January 2001, resulted from cooperation between fourteen medical, radiological...
